Last reviewed · How we verify

Spinal Anesthesia

Samuel Lunenfeld Research Institute, Mount Sinai Hospital · FDA-approved active Small molecule

Spinal anesthesia blocks nerve conduction in the spinal cord by injecting local anesthetic agents into the cerebrospinal fluid, producing rapid onset regional anesthesia of the lower body.

Spinal anesthesia blocks nerve conduction in the spinal cord by injecting local anesthetic agents into the cerebrospinal fluid, producing rapid onset regional anesthesia of the lower body. Used for Lower abdominal and pelvic surgery, Lower extremity orthopedic surgery, Cesarean section.

At a glance

Generic nameSpinal Anesthesia
Also known asNeuraxial block, Spinal anaesthesia
SponsorSamuel Lunenfeld Research Institute, Mount Sinai Hospital
Drug classLocal anesthetic (regional anesthesia technique)
TargetVoltage-gated sodium channels in nerve membranes
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Local anesthetic drugs (such as bupivacaine, lidocaine, or procaine) are injected into the subarachnoid space, where they diffuse into nerve roots and block sodium channels in sensory and motor nerves. This produces reversible loss of sensation and motor function in the lower extremities and lower abdomen, making it suitable for surgical procedures below the umbilicus. The effect is rapid (within minutes) and duration depends on the specific agent and dose used.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: